Abstract
Objective. To study the energy effect of infusions of the drug Sorbilact in the body of operated patients with cancer of the middle thoracic esophagus.
 Materials and methods. Clinical use of the drug Sorbilact was performed in 30 operated patients with cancer of the middle thoracic esophagus (the main group). Sorbilact was administered intravenously immediately after surgery, drip at a rate of 30 drops per minute for 5 days at a dose of 800 ml per day. Plasma urea concentration was determined before infusions on the 1st day after surgery, and on days 2, 3, 5 after Sorbilact infusions. The control group – 25 operated patients – was administered 5 % glucose solution at a dose of 800.0 ml.
 Results and discussion. In the first days after surgery in patients with cancer of the middle thoracic esophagus an increase in the concentration of urea in blood plasma was revealed. In the main group of operated patients after resection of the middle thoracic esophagus in repeated studies on the 2nd, 3rd, 5th day after infusions a significant decrease in the concentration of urea in blood plasma was showed. It indicates that less endogenous protein is consumed for energy purposes, and the caloric needs of the operated body are covered by intensive absorption of Sorbilact, which reduces the catabolism of internal proteins, resulting in reduced nitrogen production, which is manifested in a decrease in the concentration of urea in blood plasma and its difference. In the control group of operated patients in repeated studies on the 2nd, 3rd, 5th day after infusions an increase in plasma urea was revealed, which indicates insufficient caloric energy expenditure of the operated organism.
 Conclusions. Intravenous infusions of the drug Sorbilact according to the indicator of increment of urea in blood plasma in operated patients after resection of the middle thoracic esophagus in the early postoperative period show a pronounced energy effect.
Highlights
Clinical use of the drug Sorbilact was performed in 30 operated patients with canc er of the middle thoracic esophagus
In the main group of operated patients after resection of the middle thoracic esophagus in repeated studies on the 2nd, 3rd, 5th day after infusions a significant decrease in the concentration of urea in blood plasma was showed. It indicates that less endogenous protein is consumed for energy purposes, and the caloric needs of the operated body are covered by intensive absorption of Sorbilact, which reduces the catabolism of internal proteins, resulting in reduced nitrogen production, which is manifested in a decrease in the concentration of urea in blood plasma and its difference
ConclusionsIntravenous infusions of the drug Sorbilact according to the indicator of increment of urea in blood plasma in operated patients after resection of the middle thoracic esophagus in the early postoperative period show a pronounced energy effect
Summary
Примак С.В., Дзісь Б.Р., Дзісь Р.П., Новак В.Л., Дзісів М.П., Карпович Є.П., Чабан В.Є., Івасик В.В. Вивчити енергетичну дію інфузій препарату Сорбілакт в організмі оперованих хворих на рак середнього грудного відділу стравоходу. Сорбілакт клінічно застосовували в 30 оперованих хворих на рак середнього грудного відділу стравоходу (основна група). У перші дні після операцій у хворих виявлено підвищення концентрації сечовини в плазмі крові. В основній групі при повторних дослідженнях на 2-й, 3-й, 5-й день після інфузій встановлено істотне зниження концентрації сечовини в плазмі крові. У контрольній групі при повторних дослідженнях на 2-й, 3-й, 5-й день після інфузій виявлено зростання концентрації сечовини в плазмі крові, що свідчить про недостатнє калорійне забезпечення енергетичних витрат оперованого організму. Внутрішньовенні інфузії препарату Сорбілакт за даними показника інкремент сечовини плазми крові в оперованих хворих після резекції середнього грудного відділу стравоходу в ранньому післяопераційному періоді проявляють виражену енергетичну дію. Ключові слова: онкологічні хворі, резекція середнього грудного відділу стравоходу, інфузійний препарат Сорбілакт, показник інкремент сечовини крові. State Institution “Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine”, Lviv, Ukraine
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call